

March 18, 2010

Contact: Michael Beeuwsaert
President & CEO
Numira Biosciences Inc.
Tel: (801) 320-0682
MBeeuwsaert@numirabio.com

**NUMIRA'S BRAIN IMAGING APPLICATION HIGHLIGHTED BY CHILDREN'S HOSPITAL OF LOS ANGELES AND THE UNIVERSITY OF SOUTHERN CALIFORNIA'S KECK SCHOOL OF MEDICINE IN
*THE AMERICAN JOURNAL OF PATHOLOGY***

***CNS Publication Demonstrates Ability to Measure Changes in Brain Volume Using Numira's
Virtual Histology™ Imaging Technology***

SALT LAKE CITY, Utah, March 18, 2010 –Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, is proud to announce that its Virtual Histology technology was highlighted in the March issue of *The American Journal of Pathology*. The publication, co-authored by The Saban Research Institute at Childrens Hospital Los Angeles and the Keck School of Medicine at the University of Southern California, discussed the use of Numira's quantitative imaging technology in a study involving diseased brains.

With the combination of MicroCT, proprietary contrast agents and cutting edge software tools, Numira has developed an innovative, nondestructive way to image embryonic, newborn and adult brains in small animal models. Using this technology, our clients are able to

visualize and quantify structural tissue changes in the brain caused by various diseases such as stroke, cancer, and bacterial infections.

The paper, titled “Inhibition of Inducible Nitric Oxide Controls Pathogen Load and Brain Damage by Enhancing Phagocytosis of *Esherichia coli* K1 in Neonatal Meningitis,” was published in the March 2010 issue of *The American Journal of Pathology* . The data clearly demonstrated the ability of Numira’s technology to detect changes in the cortical area between infected and infected/treated samples.

About Numira Biosciences

Numira is a specialty contract research organization (CRO) that provides powerful imaging solutions for researchers attempting to answer questions related to the onset and progression of disease, drug efficacy, and drug safety in animal models. Through the combination of proprietary stains, high performance visualization software, and MicroCT scanners, we offer a dramatic change in how data is captured, visualized, and analyzed.

For more information on Numira Biosciences, please visit www.numirabio.com

###